EUVIMEDEUVIMED entdecken
Open Access · CC BY 4.0

In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I

Kelvyn M L Rocha, Érica C M Nascimento iD, Rafael C C de Jesus iD, João B L Martins iD

Molecules · 2024

DOI: 10.3390/molecules29174254 ↗

Kurz gefasst

Fachartikel in der Zeitschrift Molecules, 2024. Verfasst von Kelvyn M L Rocha und 3 weiteren Autor:innen. Beteiligte Einrichtung: Department of Pharmacy, Faculty of Health Sciences, University of Brasília, Brasília 70910-900, DF, Brazil. Hauptthemen laut MEDLINE: Fusion Proteins, bcr-abl, Afatinib, Protein Kinase Inhibitors, Molecular Docking Simulation. Die Arbeit wurde bisher 1-mal zitiert (Crossref) und nennt 97 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0). Gefördert von: Foundation for Research Support of the Federal District, National Council for Scientific and Technological Development, Federal District Research Support Foundation (FAPDF).

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Four afatinib derivatives were designed and modeled. These derivatives were compared to the known tyrosine-kinase inhibitors in treating Chronic Myeloid Leukemia, i.e., imatinib and ponatinib. The molecules were evaluated through computational methods, including docking studies, the non-covalent interaction index, Electron Localization and Fukui Functions, in silico ADMET analysis, QTAIM, and Heat Map analysis. The AFA(IV) candidate significantly increases the score value compared to afatinib. Furthermore, AFA(IV) was shown to be relatively similar to the ponatinib profile when evaluating a range of molecular descriptors. The addition of a methylpiperazine ring seems to be well distributed in the structure of afatinib when targeting the BCR-ABL enzyme, providing an important hydrogen bond interaction with the Asp381 residue of the DFG-switch of BCR-ABL active site residue and the AFA(IV) new chemical entities. Finally, in silico toxicity predictions show a favorable index, with some molecules presenting the loss of the irritant properties associated with afatinib in theoretical predictions.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Fusion Proteins, bcr-ablAfatinibProtein Kinase InhibitorsMolecular Docking SimulationHumansModels, MolecularComputer SimulationMutationLeukemia, Myelogenous, Chronic, BCR-ABL PositiveHydrogen BondingAntineoplastic AgentsImidazolesPyridazines

Stichwörter der Autor:innen

BCR-ABLCMLNCITKImolecular modeling

Substanzen

Fusion Proteins, bcr-ablAfatinibProtein Kinase InhibitorsAntineoplastic AgentsponatinibImidazolesPyridazines

Autor:innen und Institutionen

  • Department of Pharmacy, Faculty of Health Sciences, University of Brasília, Brasília 70910-900, DF, Brazil.
  • Computational Chemistry Laboratory, Institute of Chemistry, University of Brasília, Brasília 70910-900, DF, Brazil.

ORCID-Profile: Érica C M Nascimento, Rafael C C de Jesus, João B L Martins

Förderung

  • Foundation for Research Support of the Federal District
  • National Council for Scientific and Technological Development
  • Federal District Research Support Foundation (FAPDF)
  • Brazilian National Council for Scientific and Technological Development (CNPq)
  • Universidade de Brasília (UnB)

Zitieren

APA

Rocha, K. M. L., Nascimento, É. C. M., de Jesus, R. C. C., & Martins, J. B. L. (2024). In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I. Molecules. https://doi.org/10.3390/molecules29174254

Vancouver

Rocha KML, Nascimento ÉCM, de Jesus RCC, Martins JBL. In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I. Molecules. 2024. doi:10.3390/molecules29174254

BibTeX
@article{Rocha2024,
  author = {Rocha, Kelvyn M L and Nascimento, Érica C M and de Jesus, Rafael C C and Martins, João B L},
  title = {In Silico Molecular Modeling of Four New Afatinib Derived Molecules Targeting the Inhibition of the Mutated Form of BCR-ABL T315I},
  journal = {Molecules},
  year = {2024},
  doi = {10.3390/molecules29174254}
}
Kostenlos starten →